30.11.17: Not intended for U.S. and UK Media

Phase III trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate cancer unblinded earlyDecision follows a recommendation from an Independent Data Monitoring Committeemehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news

Related Links:

The cancer organization today largely reinstated its former advice that men with low-risk prostate cancer be offered active surveillance as the lone'preferred'initial treatment option.News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
ConclusionEven at low PSA between 0.51 and 0.99  ng/mL, detection rate was 57%. Dynamic imaging showed a time window in the first 10 min where tumour uptake is high, but no bladder activity is measured, aiding accuracy in distinction of local recurrence. Kinetic modelling provided additional information for tumour characterisation by tissue typ e.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Conclusion[18F]PSMA-1007 avid NSBLs rarely represent prostate cancer bone metastases. When identified in the absence of definite metastatic disease elsewhere, it is appropriate to classify those with SUVmax  
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
IBM Watson Health is launching a cloud-based service for orchestrating artificia...Read more on AuntMinnie.comRelated Reading: IBM showcases new iConnect Access at SIIM 2021 Reports: IBM mulling sale of Watson Health DiA partners with IBM Watson on AI Blackford, IBM team up on automated image registration Guerbet, IBM partner on AI for prostate cancer
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Purpose of review To investigate the features and optimal management of pN+ cM0 prostate cancer (PCa) according to registry-based studies. Recent findings Up to 15% of PCa patients harbor lymph node invasion (pN+) at radical prostatectomy plus lymph node dissection. Nonetheless, the optimal management strategy in this setting is not well characterized. Summary We performed a systematic review including n = 13 studies. Management strategies comprised 13 536 men undergoing observation, 11 149 adjuvant androgen deprivation therapy (aADT), 7,075 adjuvant radiotherapy (aRT) +aADT and 705 aRT. Baseline ...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: RARE UROLOGIC CANCERS: Edited by Philippe E. Spiess and Andrea Necchi Source Type: research
Purpose of review Prostate biopsy is a very commonly performed office procedure leading to the diagnosis of the most prevalent solid-organ malignancy in American men. Although the transrectal technique for prostate biopsy remains the gold standard, there is increasing interest in the transperineal approach as it offers a clean, percutaneous approach that significantly decreases the risk for infection. In this review, we discuss emerging developments in transperineal prostate biopsy that may optimize the way biopsies are performed in clinical practice. Recent findings Similarly, to transrectal biopsy, the transpe...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: PROSTATE CANCER: Edited by Matthew Cooperberg and Ashutosh K. Tewari Source Type: research
Purpose of review Whether Grade Group 1 (GG1) prostate cancer is really cancer remains controversial. Recent findings Favoring renaming GG1 with a noncancerous diagnosis are: fear of the term cancer, which will lead to overtreatment of GG1; and indolence of GG1. Favor designating GG1 as cancer are: morphologically, GG1 may be indistinguishable from GG2 to GG5 and GG1 is invasive (lacks basal cells), can show perineural invasion and extraprostatic extension; molecularly, GG1 has many of the hallmarks of prostate cancer; calling GG1 noncancer would lead to inconsistencies and confusion in reporting; sampling error...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: PROSTATE CANCER: Edited by Matthew Cooperberg and Ashutosh K. Tewari Source Type: research
Purpose of review African–American men in the USA have a higher incidence of and mortality from prostate cancer (PCa), with a longstanding debate about the cause for these worse outcomes. This review examines differences in tumour biology and socioeconomics for African–American and Non-Hispanic White (NHW) men to answer the question ‘why AA men face higher risks for lethal PCa’ and draw a management consensus to redress the imbalance. Recent findings Recent evidence from over the past 2 years suggests the reasons why African–American men face a higher risk of lethal PCa are multif...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: PROSTATE CANCER: Edited by Matthew Cooperberg and Ashutosh K. Tewari Source Type: research
In this study, treatments of intact prostate and prostate bed, with and without nodes, were simulated for 182 online adaptive fractions, and then a further 184 clinical fractions were delivered on the Ethos system. Frequency and magnitude of contour edits were recorded, as well as a range of plan quality metrics. From the fractions analyzed, 11% of AI generated contours, known as influencer contours, required no change, and 81% required minor edits in any given fraction. The frequency of target and noninfluencer organs at risk (OAR) contour editing varied substantially between different targets and noninfluencer OARs, alth...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: TET1-expressing cells are an integral part of PCa and may represent CSCs with oncogenic potential.PMID:34844636 | DOI:10.1186/s13148-021-01201-7
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Pharmaceuticals | Prednisolone | Prednisone | Prostate Cancer